| 摘要 |
<p>The invention relates to novel crystalline forms of 3-[ [3, 5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy] -phenyl]-amino]-3-oxopropanoic acid, said crystalline forms being characterised by a powder X-ray diffraction pattern having major peaks at either 2theta = 16.1 ±0.2, 20.1 ±0.2, 20.7 ±0.2, and 24.2+0.2; or 2theta = 9.0 ±0.2, 14.7 ±0.2, 19.6 ±0.2, 21.6 ±0.2, and 24.3+0.2.</p> |
